ISRCTN80267019已完成1 期
A randomised, double-blind, placebo-controlled, single and repeated dose escalation study to assess the safety, tolerability, pharmacokinetics and food effect of a new formulation of AUT00206 in healthy men and women
Autifony Therapeutics (United Kingdom)0 个研究点目标入组 41 人开始时间: 2021年9月28日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 41
研究概览
简要总结
2022 Funder report results see attached file 40474 Funder report V1 04Oct2022.pdf [1] (added 14/11/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Current participant inclusion criteria as of 21/01/2022:
- •1. Healthy male volunteer (Parts A1 and B only) or healthy female volunteer (Part A2 only).
- •2. Aged 18 - 45 years (at [first] dosing) (Part A and Part B Groups 1 and 2) or aged >18 years and targeted towards those aged >45 years (Part B Groups 3 and 4)
- •3. A BMI (Quetelet index) in the range 18.0 - 31.0 kg/m²
- •4. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
- •5. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.
- •6. Agree to follow the contraception requirements of the trial as described in the protocol/ICF.
- •7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
- •8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).
- •Previous participant inclusion criteria:
- •1. Healthy male volunteer (Parts A1 and B only) or healthy female volunteer (Part A2 only).
- •2. Aged 18 - 45 years (at [first] dosing).
- •3. A BMI (Quetelet index) in the range 18.0 - 31.0 kg/m²
- •4. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
- •5. Willingness to give written consent to participate after reading the information and consent form, and after having the opportunity to discuss the trial with the investigator or their delegate.
- •6. Agree to follow the contraception requirements of the trial as described in the protocol/ICF.
- •7. Agree not to donate blood or blood products during the study and for up to 3 months after the administration of the trial medication.
- •8. Willingness to give written consent to have data entered into The Overvolunteering Prevention System (TOPS).
排除标准
- •1. Woman who is pregnant or lactating, or pre-menopausal woman who is sexually active and not using a highly-effective method of contraception.
- •2. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the volunteer.
- •3. Presence of acute or chronic illness or history of chronic illness sufficient to invalidate the volunteer’s participation in the trial or make it unnecessarily hazardous.
- •4. Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease, post-COVID-19 syndrome (‘long COVID’), or history of any psychotic mental illness.
- •5. Surgery (eg stomach bypass) or medical condition that might affect absorption of medicines.
- •6. Presence or history of severe adverse reaction to any drug, or a history of sensitivity to AUT00206 or its excipients.
- •7. Use of a prescription medicine (except oral contraceptives in females) during the 30 days before the first dose of trial medication, or use of an over-the-counter medicine, with the exception of acetaminophen (paracetamol), during the 7 days before the first dose of trial medication.
- •8. Use of vaccine (including COVID-19 vaccine) during the 7 days, before first receipt of trial medication until the end of the study.
- •9. History of epilepsy or seizures.
- •10. Receipt of an investigational product (including prescription medicines) as part of another clinical trial within the 3 months before [first] admission to this study; in the follow-up period of another clinical trial at the time of screening for this study.
- •11. Presence or history of drug or alcohol abuse, or intake of more than 14 units of alcohol weekly.
- •12. Smoking of more than 5 cigarettes daily.
- •13. Blood pressure and heart rate in supine position at the screening examination outside the ranges: blood pressure 90–140 mm Hg systolic, 40–90 mm Hg diastolic; heart rate 40–100 beats/min.
- •14. QT value, measured at screening visit, greater than 450 msec (men) or 470 msec (women) on 12-lead ECG, using Fridericia’s formula (QTcF) for correction.
- •15. Alanine aminotransferase (AST), aspartate aminotransferase (ALT) or alkaline phosphatase (AP) = 1.5 x the upper limit of normal (ULN). A repeat is allowed on one occasion for determination of eligibility.
- •16. Possibility that the volunteer will not cooperate with the requirements of the protocol.
- •17. Positive test for hepatitis B, hepatitis C or HIV consistent with ongoing infection.
- •18. Vegans or people who are on a restricted diet for medical reasons (eg lactose intolerant); or unwilling to eat a high-fat breakfast (Part A1 and A2 only).
- •19. Positive result for suicidal ideation or behaviour using the C-SSRS, including a positive response to items 3 to 5; or a history of suicidal behaviour in the past year
- •20. Loss of more than 400 mL blood during the 3 months before the trial, eg as a blood donor.
- •21. Medical objection by General Practitioner (GP) to volunteer entering trial.
研究者
相似试验
已完成
2 期
Safety, blood levels and effects of N,N-dimethyltryptamine [DMT (SPL026)] in healthy participants and participants with major depressive disorderISRCTN63465876Small Pharma Ltd68
已完成
1 期
A study to investigate the safety and processing by the body of the drug AUT00206 in patients with schizophrenia, and to explore the effects of AUT00206 on relevant central biomarkersMental and Behavioural DisordersSchizophreniaISRCTN10534853Autifony Therapeutics (United Kingdom)24
已完成
3 期
STOP-COVID19: Superiority Trial Of Protease inhibition in COVID-19 (coronavirus infection)ISRCTN30564012niversity of Dundee406
已完成
2 期
Fulvestrant and vandetanib in advanced aromatase inhibitor resistant breast cancerCancerMetastatic breast cancerISRCTN13663157Velindre NHS Trust165
已完成
3 期
A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with hereditary angioedemaHereditary angioedema (HAE) type I or type II.Haematological DisordersHereditary Angioedema Type I or IIISRCTN14762022KalVista Pharmaceuticals Ltd136